Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LHGALOP2017: Risk-stratified Therapy for Pediatric Hodgkin Lymphoma
NCT03500133Phase 4Recruiting
- Sponsor
- Hospital de Pediatría Garrahan
- Start
- Oct 2017
- Primary completion
- Oct 2027
- Modality
- DNA Intercalators/Alkylators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 4 trial of doxorubicin, bleomycin, vinblastine, dacarbazine, etoposide in classical Hodgkin lymphoma (cHL), sponsored by Hospital de Pediatría Garrahan. Started Oct 2017; status: recruiting.
02
Drugs
doxorubicinbleomycinvinblastinedacarbazineetoposide
03
Conditions
classical Hodgkin lymphoma (cHL)
Beyond the preview
Go deeper on NCT03500133.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03500133.